Merck price target raised to $139 from $122 at Truist

Truist raised the firm’s price target on Merck to $139 from $122 and keeps a Buy rating on the shares. The company reported a Q4 earnings beat and the management expects continued growth from Keytruda, particularly in early lung cancer, ADCs, and anticipates a strong sotatercept launch in PAH, the analyst tells investors in a research note. The firm adds that it is positive on Merck’s robust cash generation, solid dividend yield, and management focus on shareholder return.